» Articles » PMID: 39330600

In Vitro Hepatic Clearance Evaluations of Per- and Polyfluoroalkyl Substances (PFAS) Across Multiple Structural Categories

Overview
Journal Toxics
Date 2024 Sep 27
PMID 39330600
Authors
Affiliations
Soon will be listed here.
Abstract

Toxicokinetic (TK) assays and in vitro-in vivo extrapolation (IVIVE) models are New Approach Methods (NAMs) used to translate in vitro points of departure to exposure estimates required to reach equivalent blood concentrations. Per- and polyfluoroalkyl substances (PFAS) are a large chemical class with wide-ranging industrial applications for which only limited toxicity data are available for human health evaluation. To address the lack of TK data, a pooled primary human hepatocyte suspension model was used with targeted liquid chromatography-mass spectrometry to investigate substrate depletion for 54 PFAS. A median value of 4.52 μL/(min x million cells) was observed across those that showed significant clearance, with 35 displaying no substrate depletion. Bayesian modeling propagated uncertainty around clearance values for use in IVIVE models. Structural evaluations showed the fluorotelomer carboxylic acids were the only PFAS carboxylates showing appreciable clearance, and per- and polyfluorosulfonamides were more readily metabolized than other PFAS sulfonates. Biotransformation product prediction, using the chemical transformation simulator, suggested hydrolysis of PFAS sulfonamides to more stable sulfonic acids, which is an important consideration for exposure modeling. This effort greatly expands the PFAS in vitro toxicokinetic dataset, enabling refined TK modeling, in silico tool development, and NAM-based human health evaluations across this important set of emerging contaminants.

Citing Articles

Per- and Polyfluoroalkyl Substances (PFAS) in Consumer Products: An Overview of the Occurrence, Migration, and Exposure Assessment.

Yang Y, Wang J, Tang S, Qiu J, Luo Y, Yang C Molecules. 2025; 30(5).

PMID: 40076219 PMC: 11901761. DOI: 10.3390/molecules30050994.


Closing the Gaps in Understanding PFAS Toxicology and Metabolism.

MacMillan D, Wetmore B, Dasgupta S, Baldwin W Toxics. 2025; 13(1.

PMID: 39853019 PMC: 11769177. DOI: 10.3390/toxics13010019.

References
1.
Wambaugh J, Wetmore B, Pearce R, Strope C, Goldsmith R, Sluka J . Toxicokinetic Triage for Environmental Chemicals. Toxicol Sci. 2015; 147(1):55-67. PMC: 4560038. DOI: 10.1093/toxsci/kfv118. View

2.
Fasano W, Sweeney L, Mawn M, Nabb D, Szostek B, Buck R . Kinetics of 8-2 fluorotelomer alcohol and its metabolites, and liver glutathione status following daily oral dosing for 45 days in male and female rats. Chem Biol Interact. 2009; 180(2):281-95. DOI: 10.1016/j.cbi.2009.03.015. View

3.
Ryu S, Yamaguchi E, Modaresi S, Agudelo J, Costales C, West M . Evaluation of 14 PFAS for permeability and organic anion transporter interactions: Implications for renal clearance in humans. Chemosphere. 2024; 361:142390. PMC: 11774580. DOI: 10.1016/j.chemosphere.2024.142390. View

4.
Louisse J, Dellafiora L, van den Heuvel J, Rijkers D, Leenders L, Dorne J . Perfluoroalkyl substances (PFASs) are substrates of the renal human organic anion transporter 4 (OAT4). Arch Toxicol. 2022; 97(3):685-696. PMC: 9968691. DOI: 10.1007/s00204-022-03428-6. View

5.
Houck K, Patlewicz G, Richard A, Williams A, Shobair M, Smeltz M . Bioactivity profiling of per- and polyfluoroalkyl substances (PFAS) identifies potential toxicity pathways related to molecular structure. Toxicology. 2021; 457:152789. DOI: 10.1016/j.tox.2021.152789. View